-
公开(公告)号：US09562096B2
公开(公告)日：2017-02-07
申请号：US14966292
申请日：2015-12-11
发明人： Yoshitaka Isumi , Toshiyuki Sato , Jun Hasegawa , Tatsuya Inoue
IPC分类号： C07K16/00 , A61K39/395 , C07K16/28 , A61K39/00
CPC分类号： C07K16/28 , A61K39/3955 , A61K2039/505 , C07K16/2803 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/70 , C07K2317/75 , C07K2317/76 , C07K2317/92
摘要： Problem to be SolvedThe present invention relates to an antibody having an anti-angiogenesis activity. More specifically, the present invention relates to an antibody against ROBO4 and a pharmaceutical composition containing the antibody. An object of the present invention is to provide an anti-ROBO4 antibody having an anti-angiogenesis effect, a pharmaceutical composition or the like comprising the antibody, a method for suppressing angiogenesis using the antibody, etc. Another object of the present invention is to provide a method for producing the antibody. The antibody of the present invention activates the downstream signal of ROBO4 and has a suppressive activity against cell migration induced by VEGF or bFGF. The antibody of the present invention also exhibits an anti-angiogenesis effect in in-vivo models.
摘要翻译： 本发明涉及具有抗血管生成活性的抗体。 更具体地，本发明涉及抗ROBO4的抗体和含有抗体的药物组合物。 本发明的目的是提供具有抗血管生成作用的抗ROBO4抗体，包含抗体的药物组合物等，抑制使用该抗体的血管生成的方法等。本发明的另一个目的是 提供生产抗体的方法。 本发明的抗体激活ROBO4的下游信号，并且具有抗VEGF或bFGF诱导的细胞迁移的抑制活性。 本发明的抗体在体内模型中也表现出抗血管生成作用。
-
公开(公告)号：US09371543B2
公开(公告)日：2016-06-21
申请号：US13728809
申请日：2012-12-27
发明人： Daisuke Nishimiya , Tatsuya Inoue
IPC分类号： C12N15/85
CPC分类号： C12N15/85 , C07K16/00 , C07K2317/14 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C12N2800/107 , C12N2830/46 , C12P21/00
摘要： A method for stably achieving high expression of a foreign gene in mammalian cells using a novel DNA element is disclosed. More specifically, the present application discloses a DNA element which enhances the activation of transcription by changing the chromatin structure around a gene locus into which a foreign gene expression unit has been introduced.
摘要翻译： 公开了一种使用新型DNA元件稳定地实现哺乳动物细胞中外源基因的高表达的方法。 更具体地，本申请公开了通过改变引入外源基因表达单元的基因座周围的染色质结构来增强转录活化的DNA元件。
-
公开(公告)号：US20200377573A1
公开(公告)日：2020-12-03
申请号：US16470951
申请日：2017-12-21
发明人： Daisuke Nishimiya , Ryuji Hashimoto , Toshiyuki Sato , Takako Kimura , Atsushi Yamasaki , Tatsuya Inoue
摘要： It is intended to provide a novel peptide. The present invention provides a peptide which comprises the amino acid sequence shown in SEQ ID NO: 30 and inhibits protease activity.
-
公开(公告)号：US10407694B2
公开(公告)日：2019-09-10
申请号：US15162294
申请日：2016-05-23
发明人： Daisuke Nishimiya , Tatsuya Inoue
摘要： Disclosed is a method for stably achieving high expression of a foreign gene in mammalian cells using a novel DNA element. More specifically disclosed is a DNA element which enhances the activation of transcription by changing the chromatin structure around a gene locus into which a foreign gene expression unit has been introduced.
-
公开(公告)号：US10808006B2
公开(公告)日：2020-10-20
申请号：US16277861
申请日：2019-02-15
发明人： Yuji Kasuya , Yasuhiro Nakagami , Emiko Hatano , Tatsuya Inoue , Kazuhiro Yoshida , Satoshi Komoriya , Yoko Murakami , Masaru Iwasaki , Atsunobu Sakamoto , Kayoko Masuda , Masako Minami , Mayumi Iizuka , Yasunori Ono , Takashi Ohnuki
摘要： The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
-
6.发明申请公开(公告)号：US20170260228A1
公开(公告)日：2017-09-14
申请号：US15510208
申请日：2015-09-09
发明人： Yuji Kasuya , Yasuhiro Nakagami , Emiko Hatano , Tatsuya Inoue , Kazuhiro Yoshida , Satoshi Komoriya , Yoko Murakami , Masaru Iwasaki , Atsunobu Sakamoto , Kayoko Masuda , Masako Minami , Mayumi Iizuka , Yasunori Ono , Takashi Ohnuki
CPC分类号： C07J71/001 , A61K9/0048 , A61K9/1647 , A61K9/204 , A61K31/58 , A61P27/02 , C07J63/008 , Y02A50/473
摘要： The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
-
公开(公告)号：US20210347836A1
公开(公告)日：2021-11-11
申请号：US17254115
申请日：2019-06-21
发明人： Tatsuya Inoue
摘要： To provide a novel pharmaceutical use of a peptide. A pharmaceutical composition for the treatment or prevention of retinitis pigmentosa, comprising a peptide which comprises the amino acid sequence shown in SEQ ID NO: 30 and inhibits the protease activity.
-
公开(公告)号：US11060108B2
公开(公告)日：2021-07-13
申请号：US16523547
申请日：2019-07-26
发明人： Daisuke Nishimiya , Tatsuya Inoue
摘要： A method for stably achieving high expression of a foreign gene in mammalian cells using a novel DNA element is disclosed. More specifically, the present application discloses a DNA element which enhances the activation of transcription by changing the chromatin structure around a gene locus into which a foreign gene expression unit has been introduced.
-
9.发明申请公开(公告)号：US20190233466A1
公开(公告)日：2019-08-01
申请号：US16277861
申请日：2019-02-15
发明人： Yuji Kasuya , Yasuhiro Nakagami , Emiko Hatano , Tatsuya Inoue , Kazuhiro Yoshida , Satoshi Komoriya , Yoko Murakami , Masaru Iwasaki , Atsunobu Sakamoto , Kayoko Masuda , Masako Minami , Mayumi Iizuka , Yasunori Ono , Takashi Ohnuki
摘要： The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
-
公开(公告)号：US20150098945A1
公开(公告)日：2015-04-09
申请号：US14397210
申请日：2013-04-26
发明人： Yoshitaka Isumi , Toshiyuki Sato , Jun Hasegawa , Tatsuya Inoue
IPC分类号： C07K16/28
CPC分类号： C07K16/28 , A61K39/3955 , A61K2039/505 , C07K16/2803 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/70 , C07K2317/75 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to an antibody having an anti-angiogenesis activity. More specifically, the present invention relates to an antibody against ROBO4 and a pharmaceutical composition containing the antibody. An object of the present invention is to provide an anti-ROBO4 antibody having an anti-angiogenesis effect, a pharmaceutical composition or the like comprising the antibody, a method for suppressing angiogenesis using the antibody, etc. Another object of the present invention is to provide a method for producing the antibody. The antibody of the present invention activates the downstream signal of ROBO4 and has a suppressive activity against cell migration induced by VEGF or bFGF. The antibody of the present invention also exhibits an anti-angiogenic effects in in-vivo models.
摘要翻译： 本发明涉及具有抗血管生成活性的抗体。 更具体地，本发明涉及抗ROBO4的抗体和含有抗体的药物组合物。 本发明的目的是提供具有抗血管生成作用的抗ROBO4抗体，包含抗体的药物组合物等，抑制使用该抗体的血管生成的方法等。本发明的另一个目的是 提供生产抗体的方法。 本发明的抗体激活ROBO4的下游信号，并且具有抗VEGF或bFGF诱导的细胞迁移的抑制活性。 本发明的抗体在体内模型中也表现出抗血管生成作用。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.017 秒)
